Clinical Trial: The Effect of Lipitor on Aortic Stenosis

Study Status: Not yet recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: The Effect of Statin Therapy (Atorvastatin) on the Progression of Calcific Valvular Aortic Stenosis

Brief Summary: The purpose of this study is to find out if an approved medicine that is used to lower cholesterol called Lipitor can slow or stop progressive narrowing of the aortic heart valve in patients with a condition called aortic stenosis. Patients who have aortic stenosis who volunteer for this study will take Lipitor for 2 years and will undergo a brief exam by a physician, labwork to measure cholesterol, and a routine heart ultrasound (sound picture of the heart) at the start of the study and every 6 months, stopping at 2 years.

Detailed Summary:

This is a prospective, single-center study assessing the effect of atorvastatin 40 mg/day (Lipitor, Pfizer) on the progression of calcific aortic stenosis in approximately 70 patients with mild to moderate calcific AS of a tricuspid or bicuspid aortic valve. As a control population, published data on historical AS cohorts will be used, employing the accepted rate of progression of a decrease in aortic valve area of 0.1 cm²/year. Additionally, also for comparison, we will prospectively study a registry of AS patients who meet our entry criteria but are either currently already being treated with or refuse to take an HMG-CoA reductase inhibitor (referred to as the "standard care" group).

All patient visits, laboratory studies, and echocardiograms will be performed at the Cleveland Clinic Foundation in Cleveland, Ohio with the exception of the 12-week visit ALT measurement which may be done at the patient's local doctor's office and the results faxed to Imaging Research. The 12-week follow-up assessment may be completed over the phone to establish any change in patient status since baseline, study medication compliance, concomitant medication use and to ascertain whether or not the appropriate laboratory test was obtained. Over a 2-year period, assessments will be conducted at baseline, 6, 12, 18, and 24 months.


Sponsor: The Cleveland Clinic

Current Primary Outcome: Rate of change in the aortic valve area as measured by transthoracic echocardiography [ Time Frame: 2 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Rate of change in the aortic valve area measured by transthoracic echocardiography compared to that of historical controls [ Time Frame: 2 years ]
  • Rate of change in aortic valve area as measured by transthoracic echocardiography compared to standard of care group [ Time Frame: 2 years ]
  • Change in the mean and peak gradients across the aortic valve as measured by transthoracic echocardiography in the treated group compared to historical control group. [ Time Frame: 2 years ]


Original Secondary Outcome: Same as current

Information By: The Cleveland Clinic

Dates:
Date Received: December 26, 2007
Date Started: August 2000
Date Completion: June 2008
Last Updated: January 9, 2008
Last Verified: May 2007